Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2), durvalumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.42; 0.94]
CAURAL (EXPLORATORY), 2019 2.60 [0.39; 17.16]
0.94 [0.27 ; 3.26 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019 2 52% 155 moderate not evaluable progression or deaths (PFS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.71 [0.49; 1.03]
CAURAL (EXPLORATORY), 2019 1.10 [0.22; 5.61]
0.73 [0.50 ; 1.05 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019 2 0% 155 moderate not evaluable objective responses (ORR)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.87 [1.55; 9.69]
CAURAL (EXPLORATORY), 2019 0.45 [0.08; 2.40]
1.49 [0.18 ; 12.08 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019 2 80% 155 moderate not evaluable AE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.24 [0.01; 5.43]
CAURAL (EXPLORATORY), 2019 1.43 [0.03; 77.69]
0.47 [0.04 ; 5.52 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019 2 0% 154 moderate not evaluable AE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.36 [0.18; 0.75]
CAURAL (EXPLORATORY), 2019 12.38 [1.29; 118.34]
1.79 [0.06 ; 56.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019 2 88% 154 moderate not evaluable AE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.27 [0.63; 16.86]
CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
2.61 [0.57 ; 11.92 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019 2 0% 154 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.24; 1.67]
0.63 [0.24 ; 1.67 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable SAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.73 [0.81; 3.73]
CAURAL (EXPLORATORY), 2019 1.64 [0.32; 8.45]
1.71 [0.86 ; 3.43 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019 2 0% 154 moderate not evaluable STRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.33; 3.10]
CAURAL (EXPLORATORY), 2019 0.33 [0.01; 10.81]
0.92 [0.32 ; 2.65 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019 2 0% 154 moderate not evaluable TRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.19 [0.08; 0.46]
CAURAL (EXPLORATORY), 2019 2.33 [0.41; 13.17]
0.59 [0.05 ; 6.90 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019 2 84% 154 moderate not evaluable TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.13 [0.05; 0.36]
CAURAL (EXPLORATORY), 2019 7.08 [0.34; 148.71]
0.74 [0.02 ; 34.86 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019 2 83% 154 moderate not evaluable TRAE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable TRAE leading to discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.24; 4.26]
1.02 [0.24 ; 4.26 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Anaemia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
0.08 [0.00 ; 1.41 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Asthenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
0.25 [0.01 ; 5.61 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Colitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Constipation TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Dyspepsia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Fatigue TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
0.08 [0.00 ; 1.41 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.16 [0.01; 3.32]
0.16 [0.01 ; 3.32 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Nausea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
0.25 [0.01 ; 5.61 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.09 [0.01; 1.76]
0.09 [0.01 ; 1.76 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
1.02 [0.06 ; 16.62 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Rash TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
1.02 [0.06 ; 16.62 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Arthralgia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Back pain AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Constipation AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Cough AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Diarrhoea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 1.44 [0.04; 46.58]
1.44 [0.04 ; 46.58 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Dry skin AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Dyspnoea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Nausea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Neutropenia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 3.07 [0.13; 74.70]
3.07 [0.13 ; 74.70 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Pneumonia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 3.07 [0.13; 74.70]
3.07 [0.13 ; 74.70 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Pruritus AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Rash AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Stomatitis AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-27 23:39 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169
- treatments: 854,374,953,672,1080,1560,1073,862